Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

EDCTP approves € 80 M of funding to boost HIV/AIDS, TB and malaria research

04.06.2008
The European & Developing Countries Clinical Trials Partnership (EDCTP) has approved over € 80 million for research into prevention of HIV/AIDS, tuberculosis and malaria in Africa. This sum is the highest amount of EDCTP funding approved to date. The approval marks an increase of European investment in research into the three poverty-related diseases and is expected to significantly enhance cooperation between European and African researchers.

EDCTP is a partnership of 14 European Member States plus Norway, Switzerland and sub-Saharan countries. The Partnership aims to reduce the global burden of HIV/AIDS, TB and malaria by pooling resources for conducting clinical trials in sub-Saharan Africa. The current approval of funding consists of a contribution from the European Commission of € 40 M, to be matched by European Member States and third parties. The projects involve 12 European countries and 22 sub-Saharan African countries. Funding was approved in the following areas:

Tuberculosis Vaccines
Malaria Treatment
Malaria in Pregnancy
Malaria Vaccines
Ethics review capacity
WHO regulatory affairs
Networks of Excellence
Senior Fellowships
Additional funding in the areas of HIV treatment, vaccines and microbicides, TB treatment and Networks of Excellence is expected to be approved in the second half of 2008.

The projects on TB and malaria that will be funded combine clinical trials with capacity building and networking activities. By integrating these activities EDCTP aims to enhance sustainability of conducting clinical trials on the African continent. A number of projects focuses on creating and developing capacity for ethics review of clinical trials and of enhancing the regulatory framework needed for approval of medicines in Africa. This enables African countries to conduct high-quality and ethically sound clinical trials, and to assess the safety and efficacy of all medicines that enter the African market.

EU Member State commitment and African leadership very encouraging
European Science and Research Commissioner Janez Potocnik underlined the integration of policies achieved by the partnership: "This decision from the EDCTP General Assembly shows the commitment of the participating countries and the European Commission in the fight against the three main poverty-related diseases in and for Africa. We're confident that our cooperation with African researchers will make a difference".

Prof. Charles Mgone, EDCTP’s executive director expressed the significance of the approval when he said: “This is a very significant milestone for collaboration between north and south in the fight against the three main diseases of poverty namely HIV/AIDS, tuberculosis and malaria. It is also very gratifying to note that among the 26 projects approved for funding 22 have African scientists based in Africa as their principal investigators. This underscores EDCTP’s objective of fostering a genuine partnership and enhancing clinical research capacity in Africa.”

About EDCTP
EDCTP aims through research integration to accelerate the development of new or improved drugs, vaccines, diagnostics and microbicides against HIV/AIDS, malaria and tuberculosis, with a focus on phase II and III clinical trials in sub-Saharan Africa.

EDCTP supports integrated multicentre projects which combine clinical trials, capacity building and networking. The aim of integrating these three activities is to develop the capacity to conduct clinical trials in sub-Saharan Africa in a sustainable way.

The basis of EDCTP is partnership. It unites 14 participating European Union (EU) Member States plus Norway and Switzerland with sub-Saharan African countries. The partnership helps EU Member States to integrate and coordinate their own national research and development programmes and form partnerships with their African counterparts.

Ilona van den Brink | alfa
Further information:
http://ec.europa.eu/research/index.cfm
http://www.edctp.org/index.php?id=428

More articles from Health and Medicine:

nachricht Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Foods of the future
15.08.2018 | Georg-August-Universität Göttingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Smallest transistor worldwide switches current with a single atom in solid electrolyte

17.08.2018 | Physics and Astronomy

Robots as Tools and Partners in Rehabilitation

17.08.2018 | Information Technology

Climate Impact Research in Hannover: Small Plants against Large Waves

17.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>